Peptide questions, checked carefully.Independent peptide information · Sources on every review · No sales · No dosing.
The Peptide Field
Menu

Sources · 200 checked

Sources checked for each answer.

Search the sources behind the evidence pages. Find drug labels, official agency pages, studies in people, and early studies in cells or animals. Each source shows which peptide evidence briefs cite it.

200Sources checked
242Times used
33Peptide briefs covered

200 sources of 200

Each source appears once. Open a peptide brief to see how it uses this source.
Source types, in plain language

Regulatory & labels are official agency records and product labels. Human trials study people. Trial plans and status are public records of planned or ongoing studies and may not include results. Human pharmacology studies how a substance acts in people. Reviews & preclinical includes research reviews and early studies in cells or animals.

01
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-08-30

OZEMPIC (semaglutide) prescribing information, revised 05/2026

Peptide briefs that use this sourceSemaglutide
Open source
02
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-08-30

RYBELSUS (semaglutide) prescribing information, revised 10/2025

Peptide briefs that use this sourceSemaglutide
Open source
03
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-08-30

WEGOVY (semaglutide) prescribing information, revised 06/2026

Peptide briefs that use this sourceSemaglutide
Open source
06
PreclinicalPubMed · Journal of Medicinal Chemistry · 2015Checked 2026-08-30

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

Peptide briefs that use this sourceSemaglutide
Open source
07
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA substance record: semaglutide identity (not an approval record)

Peptide briefs that use this sourceSemaglutide
Open source
08
Anti-dopingWorld Anti-Doping Agency · 2026Checked 2026-08-30

2026 Monitoring Program

Peptide briefs that use this sourceSemaglutide
Open source
09
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Insulin: patient and product overview

Peptide briefs that use this sourceInsulin
Open source
10
Drug labelDailyMed · National Library of Medicine · 2026Checked 2026-08-30

HUMALOG (insulin lispro) label, updated June 2026

Peptide briefs that use this sourceInsulin
Open source
11
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-08-30

HUMALOG (insulin lispro) FDA prescribing information, revised 05/2025

Peptide briefs that use this sourceInsulin
Open source
12
Randomized trialPubMed · New England Journal of Medicine · 1993Checked 2026-08-30

The effect of intensive treatment of diabetes on long-term complications in insulin-dependent diabetes mellitus

Peptide briefs that use this sourceInsulin
Open source
13
Randomized trialPubMed · Diabetes · 1997Checked 2026-08-30

Hypoglycemia in the Diabetes Control and Complications Trial

Peptide briefs that use this sourceInsulin
Open source
14
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA approves the first rapid-acting insulin biosimilar product for diabetes

Peptide briefs that use this sourceInsulin
Open source
15
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Biosimilars basics for patients

Peptide briefs that use this sourceInsulin
Open source
17
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-08-30

MOUNJARO (tirzepatide) prescribing information, revised January 2026

Peptide briefs that use this sourceTirzepatide
Open source
18
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-08-30

ZEPBOUND (tirzepatide) prescribing information, revised February 2026

Peptide briefs that use this sourceTirzepatide
Open source
19
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA approval letter: Mounjaro heart-risk indication, August 27, 2026

Peptide briefs that use this sourceTirzepatide
Open source
20
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA supplement letter: Zepbound cardiovascular-trial information, August 26, 2026

Peptide briefs that use this sourceTirzepatide
Open source
21
FDA reviewU.S. Food and Drug Administration · 2022Checked 2026-08-30

FDA review: tirzepatide's 39-amino-acid structure

Peptide briefs that use this sourceTirzepatide
Open source
22
Randomized trialPubMed · New England Journal of Medicine · 2022Checked 2026-08-30

Tirzepatide once weekly for the treatment of obesity

Peptide briefs that use this sourceTirzepatide
Open source
23
Randomized trialPubMed · New England Journal of Medicine · 2021Checked 2026-08-30

Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes

Peptide briefs that use this sourceTirzepatide
Open source
24
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-07-23

July 2026 PCAC briefing on BPC-157-related bulk drug substances

Peptide briefs that use this sourceBPC-157
Open source
26
Science reviewPubMed · Pharmaceutics · 2026Checked 2026-07-23

BPC-157 as an investigational peptide therapeutic: translational development barriers

Peptide briefs that use this sourceBPC-157
Open source
27
Human pilotPubMed · Alternative Therapies in Health and Medicine · 2025Checked 2026-07-23

Safety of intravenous infusion of BPC157 in humans: a pilot study

Peptide briefs that use this sourceBPC-157
Open source
28
PreclinicalPubMed · Journal of Applied Physiology · 2011Checked 2026-07-23

Promoting effect of BPC 157 on tendon healing: tendon outgrowth, cell survival, and migration

Peptide briefs that use this sourceBPC-157
Open source
30
Trial registryClinicalTrials.gov · 2026Checked 2026-07-23

BPC 157 for acute hamstring muscle strain repair

Peptide briefs that use this sourceBPC-157
Open source
31
Randomized trialPubMed · Journal of Clinical Endocrinology & Metabolism · 2006Checked 2026-07-23

Prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults

Peptide briefs that use this sourceCJC-1295
Open source
32
Human pharmacologyPubMed · Journal of Clinical Endocrinology & Metabolism · 2006Checked 2026-07-23

Pulsatile GH secretion during continuous stimulation by CJC-1295

Peptide briefs that use this sourceCJC-1295
Open source
33
FDA reviewU.S. Food and Drug Administration · 2024Checked 2026-07-23

CJC-1295 pharmacy compounding advisory review

Peptide briefs that use this sourceCJC-1295
Open source
34
Human pharmacologyPubMed · Pharmaceutical Research · 1999Checked 2026-07-23

Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers

Peptide briefs that use this sourceIpamorelin
Open source
35
Randomized trialPubMed · International Journal of Colorectal Disease · 2015Checked 2026-07-23

Randomized proof-of-concept study of ipamorelin for postoperative ileus

Peptide briefs that use this sourceIpamorelin
Open source
36
Drug labelU.S. Food and Drug Administration · 2024Checked 2026-07-23

VICTOZA (liraglutide) prescribing information

Peptide briefs that use this sourceLiraglutide
Open source
37
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-07-23

SAXENDA (liraglutide) prescribing information

Peptide briefs that use this sourceLiraglutide
Open source
38
Randomized trialPubMed · New England Journal of Medicine · 2016Checked 2026-07-23

Liraglutide and cardiovascular outcomes in type 2 diabetes

Peptide briefs that use this sourceLiraglutide
Open source
39
Human pharmacologyPubMed · The Lancet · 2022Checked 2026-07-23

LY3437943 in people with type 2 diabetes: a phase 1b randomized trial

Peptide briefs that use this sourceRetatrutide
Open source
40
Randomized trialPubMed · The Lancet · 2023Checked 2026-07-23

Retatrutide for people with type 2 diabetes: a phase 2 randomized trial

Peptide briefs that use this sourceRetatrutide
Open source
41
Randomized trialPubMed · New England Journal of Medicine · 2023Checked 2026-07-23

Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial

Peptide briefs that use this sourceRetatrutide
Open source
42
Randomized trialPubMed · Nature Medicine · 2024Checked 2026-07-23

Retatrutide for metabolic dysfunction-associated steatotic liver disease

Peptide briefs that use this sourceRetatrutide
Open source
43
Trial registryClinicalTrials.gov · 2026Checked 2026-07-23

TRIUMPH-1 phase 3 study record

Peptide briefs that use this sourceRetatrutide
Open source
44
Trial registryClinicalTrials.gov · 2026Checked 2026-07-23

TRIUMPH-2 phase 3 study record

Peptide briefs that use this sourceRetatrutide
Open source
45
Trial registryClinicalTrials.gov · 2026Checked 2026-07-23

TRIUMPH-3 phase 3 study record

Peptide briefs that use this sourceRetatrutide
Open source
46
ReferenceEli Lilly and Company · 2026Checked 2026-07-24

TRIUMPH-1 early sponsor-reported results

Peptide briefs that use this sourceRetatrutide
Open source
47
ReferenceEli Lilly and Company · 2026Checked 2026-07-24

TRIUMPH-2 and TRIUMPH-3 early sponsor-reported results

Peptide briefs that use this sourceRetatrutide
Open source
48
Randomized trialPubMed · The Lancet · 2021Checked 2026-08-30

Cagrilintide for weight management: randomized phase 2 trial

Peptide briefs that use this sourceCagrilintide
Open source
49
Randomized trialPubMed · New England Journal of Medicine · 2025Checked 2026-08-30

Coadministered cagrilintide and semaglutide in adults with overweight or obesity

Peptide briefs that use this sourceCagrilintide
Open source
50
Trial registryClinicalTrials.gov · 2026Checked 2026-08-30

Cagrilintide clinical study record

Peptide briefs that use this sourceCagrilintide
Open source
51
Trial registryClinicalTrials.gov · 2021Checked 2026-08-30

Phase 2 cagrilintide study record (NNC0174-0833)

Peptide briefs that use this sourceCagrilintide
Open source
52
PreclinicalPubMed · Journal of Pharmacology and Experimental Therapeutics · 2021Checked 2026-08-30

AM833 pharmacology and cagrilintide identity

Peptide briefs that use this sourceCagrilintide
Open source
53
PreclinicalPubMed · Journal of Medicinal Chemistry · 2021Checked 2026-08-30

Development of Cagrilintide, a Long-Acting Amylin Analogue

Peptide briefs that use this sourceCagrilintide
Open source
54
Human pharmacologyPubMed · The Lancet · 2021Checked 2026-08-30

Cagrilintide with semaglutide: human exposure and effects

Peptide briefs that use this sourceCagrilintide
Open source
55
ReferenceNovo Nordisk · 2026Checked 2026-08-30

Q2 2026 research pipeline: NN9833 is cagrilintide

Peptide briefs that use this sourceCagrilintide
Open source
56
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA substance record: cagrilintide identity (not an approval record)

Peptide briefs that use this sourceCagrilintide
Open source
57
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA identity record for elamipretide and SS-31

Peptide briefs that use this sourceSS-31
Open source
58
RegulatoryU.S. Food and Drug Administration · 2025Checked 2026-08-30

FDA grants accelerated approval to Forzinity for Barth syndrome

Peptide briefs that use this sourceSS-31
Open source
59
FDA reviewU.S. Food and Drug Administration · 2025Checked 2026-08-30

Forzinity Drug Trials Snapshot

Peptide briefs that use this sourceSS-31
Open source
60
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-08-30

Forzinity prescribing information

Peptide briefs that use this sourceSS-31
Open source
61
RegulatoryU.S. Food and Drug Administration · 2025Checked 2026-08-30

Forzinity FDA approval letter

Peptide briefs that use this sourceSS-31
Open source
62
Randomized trialPubMed · 2020Checked 2026-08-30

TAZPOWER randomized Barth syndrome study

Peptide briefs that use this sourceSS-31
Open source
63
Randomized trialPubMed · 2023Checked 2026-08-30

MMPOWER-3 phase 3 mitochondrial-myopathy study

Peptide briefs that use this sourceSS-31
Open source
64
Randomized trialPubMed · 2020Checked 2026-08-30

MMPOWER-2 mitochondrial-myopathy study

Peptide briefs that use this sourceSS-31
Open source
65
Randomized trialPubMed · 2020Checked 2026-08-30

PROGRESS-HF elamipretide heart-failure study

Peptide briefs that use this sourceSS-31
Open source
66
Human pilotPubMed · 2021Checked 2026-08-30

Elamipretide study in healthy older adults

Peptide briefs that use this sourceSS-31
Open source
67
Trial registryClinicalTrials.gov · 2017Checked 2026-08-30

TAZPOWER clinical study record

Peptide briefs that use this sourceSS-31
Open source
68
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA Global Substance Registration System record for Cerebrolysin

Peptide briefs that use this sourceCerebrolysin
Open source
69
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA orphan drug designation explainer

Peptide briefs that use this sourceCerebrolysin
Open source
70
Drug labelAustrian Federal Office for Safety in Health Care (BASG) · 2021Checked 2026-08-30

Cerebrolysin Austrian product information

Peptide briefs that use this sourceCerebrolysin
Open source
71
Randomized trialPubMed · Stroke · 2012Checked 2026-08-30

CASTA randomized acute stroke trial

Peptide briefs that use this sourceCerebrolysin
Open source
72
Trial registryClinicalTrials.gov · 2009Checked 2026-08-30

CASTA trial record (NCT00868283)

Peptide briefs that use this sourceCerebrolysin
Open source
73
Science reviewPubMed · Cochrane Database of Systematic Reviews · 2023Checked 2026-08-30

Cochrane review of Cerebrolysin for acute ischemic stroke

Peptide briefs that use this sourceCerebrolysin
Open source
74
Science reviewPubMed · Cochrane Database of Systematic Reviews · 2019Checked 2026-08-30

Cochrane review of Cerebrolysin for vascular dementia

Peptide briefs that use this sourceCerebrolysin
Open source
75
Randomized trialPubMed · Journal of Neural Transmission · 2002Checked 2026-08-30

Randomized Cerebrolysin study in Alzheimer's disease

Peptide briefs that use this sourceCerebrolysin
Open source
76
ReferencePubMed · Drug Testing and Analysis · 2015Checked 2026-08-30

Peptide profile of an Internet-obtained Cerebrolysin sample

Peptide briefs that use this sourceCerebrolysin
Open source
77
ReferencePubMed · Journal of Medical Life · 2024Checked 2026-08-30

Comparison of Cerebrolysin with other peptide preparations

Peptide briefs that use this sourceCerebrolysin
Open source
78
FDA reviewU.S. Food and Drug Administration · 2024Checked 2026-08-30

FDA review of Kisspeptin-10 for pharmacy compounding

Peptide briefs that use this sourceKisspeptin-10
Open source
79
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA substance identity record for Kisspeptin-10

Peptide briefs that use this sourceKisspeptin-10
Open source
80
Human pharmacologyPubMed · Journal of Clinical Endocrinology and Metabolism · 2011Checked 2026-08-30

Kisspeptin-10 and reproductive hormone release in healthy men

Peptide briefs that use this sourceKisspeptin-10
Open source
81
Human pharmacologyPubMed · Journal of Clinical Endocrinology and Metabolism · 2026Checked 2026-08-30

Intermittent and continuous Kisspeptin-10 exposure in healthy men

Peptide briefs that use this sourceKisspeptin-10
Open source
82
Human pharmacologyPubMed · Journal of Clinical Endocrinology and Metabolism · 2015Checked 2026-08-30

Direct human comparison of Kisspeptin-10 and Kisspeptin-54

Peptide briefs that use this sourceKisspeptin-10
Open source
83
FDA reviewU.S. Food and Drug Administration · 2024Checked 2026-08-30

FDA identity overview for thymosin alpha-1

Peptide briefs that use this sourceThymosin alpha-1
Open source
84
FDA reviewU.S. Food and Drug Administration · 2025Checked 2026-08-30

FDA review of the separate thymosin beta-4 fragment called TB-500

Peptide briefs that use this sourceThymosin alpha-1TB-500
Open source
85
FDA reviewU.S. Food and Drug Administration · 2024Checked 2026-08-30

FDA evaluation of thymosin alpha-1 for pharmacy compounding

Peptide briefs that use this sourceThymosin alpha-1
Open source
88
Randomized trialPubMed · Critical Care · 2022Checked 2026-08-30

TRACE trial in acute pancreatitis

Peptide briefs that use this sourceThymosin alpha-1
Open source
89
Randomized trialPubMed · Critical Care · 2013Checked 2026-08-30

Earlier ETASS sepsis trial

Peptide briefs that use this sourceThymosin alpha-1
Open source
90
Randomized trialPubMed · Hepatology · 1999Checked 2026-08-30

Randomized chronic hepatitis B trial

Peptide briefs that use this sourceThymosin alpha-1
Open source
91
Drug labelU.S. Food and Drug Administration · 2024Checked 2026-07-23

EGRIFTA SV (tesamorelin) prescribing information

Peptide briefs that use this sourceTesamorelin
Open source
92
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-07-23

EGRIFTA WR (tesamorelin) prescribing information

Peptide briefs that use this sourceTesamorelin
Open source
93
Randomized trialPubMed · Journal of Acquired Immune Deficiency Syndromes · 2010Checked 2026-07-23

Tesamorelin in HIV-associated abdominal fat accumulation

Peptide briefs that use this sourceTesamorelin
Open source
94
FDA reviewU.S. Food and Drug Administration · 1991Checked 2026-07-23

Geref (sermorelin acetate) approval package

Peptide briefs that use this sourceSermorelin
Open source
95
RegulatoryFederal Register · U.S. Food and Drug Administration · 2013Checked 2026-07-23

FDA determination that Geref was not withdrawn for safety or effectiveness

Peptide briefs that use this sourceSermorelin
Open source
96
RegulatoryopenFDA · U.S. Food and Drug Administration · 2026Checked 2026-07-23

Current Drugs@FDA records for sermorelin

Peptide briefs that use this sourceSermorelin
Open source
97
Science reviewPubMed · BioDrugs · 1999Checked 2026-07-23

Sermorelin in diagnosis and treatment of pediatric growth hormone deficiency

Peptide briefs that use this sourceSermorelin
Open source
98
ReferenceU.S. Food and Drug Administration Global Substance Registration System · 2026Checked 2026-08-30

Gonadorelin substance identity record (UNII 9O7312W37G)

Peptide briefs that use this sourceGonadorelin
Open source
99
RegulatoryU.S. Food and Drug Administration · 1982Checked 2026-08-30

FACTREL (gonadorelin) Drugs@FDA record, NDA 018123

Peptide briefs that use this sourceGonadorelin
Open source
100
RegulatoryU.S. Food and Drug Administration · 1989Checked 2026-08-30

LUTREPULSE KIT (gonadorelin) Drugs@FDA record, NDA 019687

Peptide briefs that use this sourceGonadorelin
Open source
101
RegulatoryU.S. Food and Drug Administration · 1989Checked 2026-08-30

Lutrepulse orphan-drug approval record

Peptide briefs that use this sourceGonadorelin
Open source
102
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Cattle estrous-cycle resource and FDA-approved animal drugs

Peptide briefs that use this sourceGonadorelin
Open source
103
Drug labelDailyMed · U.S. National Library of Medicine · 2026Checked 2026-08-30

FACTREL cattle product label and gonadorelin identity

Peptide briefs that use this sourceGonadorelin
Open source
104
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Wholesale Peptide warning letter

Peptide briefs that use this sourceGonadorelin
Open source
105
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Human drug compounding: FDA questions and answers

Peptide briefs that use this sourceGonadorelinGHRP-6
Open source
106
Trial registryClinicalTrials.gov · 2026Checked 2026-08-30

Gonadorelin study in hypogonadotropic hypogonadism

Peptide briefs that use this sourceGonadorelin
Open source
107
Human clinical studyPubMed · 1986Checked 2026-08-30

Gonadorelin treatment in hypothalamic amenorrhea

Peptide briefs that use this sourceGonadorelin
Open source
108
Human clinical studyPubMed · 1990Checked 2026-08-30

Lutrepulse study in women with hypothalamic amenorrhea

Peptide briefs that use this sourceGonadorelin
Open source
109
Human clinical studyPubMed · 2019Checked 2026-08-30

Nonrandomized gonadorelin study in congenital hypogonadotropic hypogonadism

Peptide briefs that use this sourceGonadorelin
Open source
110
ReferenceU.S. Food and Drug Administration Global Substance Registration System · 2026Checked 2026-08-30

GHRP-6 substance identity record (UNII 4H7N4I6X6A)

Peptide briefs that use this sourceGHRP-6
Open source
111
Human pharmacologyPubMed · 1989Checked 2026-08-30

Growth hormone response to GHRP-6 in healthy men

Peptide briefs that use this sourceGHRP-6
Open source
112
Human pharmacologyPubMed · 1998Checked 2026-08-30

GHRP-6 growth hormone response and GHRH dependence

Peptide briefs that use this sourceGHRP-6
Open source
113
Human pharmacologyPubMed · 2012Checked 2026-08-30

GHRP-6 exposure study in healthy men

Peptide briefs that use this sourceGHRP-6
Open source
114
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Bulk drug substances used in compounding under section 503A

Peptide briefs that use this sourceGHRP-6Semax
Open source
115
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

503A Category 3 bulk drug substances nominated without adequate support

Peptide briefs that use this sourceGHRP-6GHK-CuLL-37
Open source
116
RegulatoryU.S. Food and Drug Administration · 2019Checked 2026-08-30

United Pharmacy warning letter

Peptide briefs that use this sourceGHRP-6
Open source
117
ReferenceU.S. Food and Drug Administration Global Substance Registration System · 2026Checked 2026-07-23

TB-500 substance record

Peptide briefs that use this sourceTB-500
Open source
118
Randomized trialPubMed · Archives of Facial Plastic Surgery · 2006Checked 2026-07-23

Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

Peptide briefs that use this sourceGHK-Cu
Open source
119
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-07-23

FDA briefing document for MOTS-c-related bulk drug substances

Peptide briefs that use this sourceMOTS-c
Open source
120
ReferenceU.S. Food and Drug Administration Global Substance Registration System · 2026Checked 2026-07-23

MOTS-c substance record

Peptide briefs that use this sourceMOTS-c
Open source
121
FDA reviewU.S. Food and Drug Administration · 2024Checked 2026-07-23

FDA briefing document for AOD-9604-related bulk drug substances

Peptide briefs that use this sourceAOD-9604
Open source
122
RegulatoryU.S. Food and Drug Administration · 2021Checked 2026-07-23

Sterile compounded AOD-9604 recall for lack of sterility assurance

Peptide briefs that use this sourceAOD-9604
Open source
123
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-07-23

FDA briefing document for epitalon-related bulk drug substances

Peptide briefs that use this sourceEpitalon
Open source
124
PreclinicalPubMed · Biogerontology · 2025Checked 2026-07-23

Epitalon and telomere length in human cell lines

Peptide briefs that use this sourceEpitalon
Open source
125
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-07-23

July 2026 Pharmacy Compounding Advisory Committee meeting

Peptide briefs that use this sourceEpitalonSemaxDSIP
Open source
126
Drug labelU.S. Food and Drug Administration · 2020Checked 2026-07-23

VYLEESI (bremelanotide) prescribing information

Peptide briefs that use this sourceBremelanotide
Open source
127
Randomized trialPubMed · Obstetrics & Gynecology · 2019Checked 2026-07-23

Bremelanotide for HSDD: two randomized phase 3 trials

Peptide briefs that use this sourceBremelanotide
Open source
128
FDA reviewU.S. Food and Drug Administration · 2019Checked 2026-07-23

Vyleesi multidisciplinary review

Peptide briefs that use this sourceBremelanotide
Open source
129
Drug labelU.S. Food and Drug Administration · 2024Checked 2026-07-23

SCENESSE (afamelanotide) prescribing information

Peptide briefs that use this sourceAfamelanotide
Open source
130
Randomized trialPubMed · New England Journal of Medicine · 2015Checked 2026-07-23

Afamelanotide for erythropoietic protoporphyria

Peptide briefs that use this sourceAfamelanotide
Open source
131
RegulatoryU.S. Food and Drug Administration · 2019Checked 2026-07-23

Afamelanotide orphan drug designation and approval

Peptide briefs that use this sourceAfamelanotide
Open source
132
Drug labelU.S. Food and Drug Administration · 2024Checked 2026-07-23

FORTEO (teriparatide) prescribing information

Peptide briefs that use this sourceTeriparatide
Open source
133
Randomized trialPubMed · New England Journal of Medicine · 2001Checked 2026-07-23

Parathyroid hormone for postmenopausal osteoporosis

Peptide briefs that use this sourceTeriparatide
Open source
134
Randomized trialPubMed · Clinical Orthopaedics and Related Research · 2016Checked 2026-07-23

Teriparatide and femoral-neck fracture healing

Peptide briefs that use this sourceTeriparatide
Open source
135
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-07-23

TYMLOS (abaloparatide) prescribing information

Peptide briefs that use this sourceAbaloparatide
Open source
136
Randomized trialPubMed · JAMA · 2016Checked 2026-07-23

Abaloparatide vs placebo on new vertebral fractures: ACTIVE

Peptide briefs that use this sourceAbaloparatide
Open source
137
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-07-23

GATTEX (teduglutide) prescribing information

Peptide briefs that use this sourceTeduglutide
Open source
138
Randomized trialPubMed · Gastroenterology · 2012Checked 2026-07-23

Teduglutide reduces parenteral support in short bowel syndrome

Peptide briefs that use this sourceTeduglutide
Open source
139
RegulatoryU.S. Food and Drug Administration · 2019Checked 2026-07-23

Teduglutide orphan drug designation and approval

Peptide briefs that use this sourceTeduglutide
Open source
140
Human pilotPubMed · Life Sciences · 1996Checked 2026-07-31

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide, in a pilot phase-I clinical study

Peptide briefs that use this sourceMelanotan II
Open source
141
Human pharmacologyPubMed · International Journal of Impotence Research · 2000Checked 2026-07-31

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II

Peptide briefs that use this sourceMelanotan II
Open source
142
ReferencePubMed · Clinical Toxicology · 2012Checked 2026-07-31

Melanotan II injection resulting in systemic toxicity and rhabdomyolysis

Peptide briefs that use this sourceMelanotan II
Open source
143
ReferencePubMed Central · CEN Case Reports · 2020Checked 2026-07-31

Melanotan II: a possible cause of renal infarction — review of the literature and case report

Peptide briefs that use this sourceMelanotan II
Open source
144
ReferencePubMed · Sexual Medicine · 2021Checked 2026-07-31

Melanotan tanning injection: a rare cause of priapism

Peptide briefs that use this sourceMelanotan II
Open source
145
ReferencePubMed · Dermatology · 2014Checked 2026-07-31

Melanoma associated with the use of melanotan-II

Peptide briefs that use this sourceMelanotan II
Open source
146
ReferencePubMed · International Journal of Oral and Maxillofacial Surgery · 2025Checked 2026-07-31

Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?

Peptide briefs that use this sourceMelanotan II
Open source
147
Science reviewPubMed · International Journal of Dermatology · 2017Checked 2026-07-31

Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review

Peptide briefs that use this sourceMelanotan II
Open source
148
ReferencePubMed · Drug Testing and Analysis · 2015Checked 2026-07-31

Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the internet

Peptide briefs that use this sourceMelanotan II
Open source
149
Drug labelDailyMed · U.S. National Library of Medicine · 2026Checked 2026-07-31

SCENESSE (afamelanotide) prescribing information

Peptide briefs that use this sourceMelanotan II
Open source
150
Drug labelDailyMed · U.S. National Library of Medicine · 2026Checked 2026-07-31

VYLEESI (bremelanotide) prescribing information

Peptide briefs that use this sourceMelanotan II
Open source
151
RegulatoryEuropean Medicines Agency · 2014Checked 2026-07-31

Scenesse European public assessment report

Peptide briefs that use this sourceMelanotan II
Open source
152
ReferenceCancer Research UK · 2026Checked 2026-07-31

Fake tan and melanotan injections

Peptide briefs that use this sourceMelanotan II
Open source
153
RegulatoryTherapeutic Goods Administration · 2024Checked 2026-07-31

Individual issued 27 infringement notices for allegedly supplying melanotan II

Peptide briefs that use this sourceMelanotan II
Open source
154
Anti-dopingWorld Anti-Doping Agency · 2026Checked 2026-07-31

WADA Prohibited List

Peptide briefs that use this sourceMelanotan II
Open source
155
Anti-dopingU.S. Anti-Doping Agency · 2026Checked 2026-07-31

2026 WADA Prohibited List summary

Peptide briefs that use this sourceMelanotan II
Open source
156
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA evaluation of Semax-related bulk drug substances

Peptide briefs that use this sourceSemax
Open source
157
RegulatoryElectronic Code of Federal Regulations · 2026Checked 2026-08-30

21 CFR 216.23 bulk drug substances list

Peptide briefs that use this sourceSemaxDSIPLL-37
Open source
158
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA substance record for Semax free base

Peptide briefs that use this sourceSemax
Open source
159
Human clinical studyPubMed · 2018Checked 2026-08-30

The efficacy of Semax in the treatment of patients at different stages of ischemic stroke

Peptide briefs that use this sourceSemax
Open source
160
Human clinical studyPubMed · 1997Checked 2026-08-30

Effectiveness of Semax in acute period of hemispheric ischemic stroke

Peptide briefs that use this sourceSemax
Open source
161
Human pharmacologyPubMed · Frontiers in Human Neuroscience · 2018Checked 2026-08-30

Resting brain-scan study in 24 healthy adults

Peptide briefs that use this sourceSemax
Open source
162
ReferencePubChem · 2026Checked 2026-08-30

N-acetyl Semax amidate identity record

Peptide briefs that use this sourceSemax
Open source
163
ReferenceRegulatory Affairs Professionals Society · 2026Checked 2026-08-30

FDA advisory committee backs two more peptides, rejects one for compounding list

Peptide briefs that use this sourceSemax
Open source
164
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA substance record for Selank, Selanc, and TP-7

Peptide briefs that use this sourceSelank
Open source
165
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA current substance record showing the related Selank diacetate form

Peptide briefs that use this sourceSelank
Open source
166
Randomized trialPubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2008Checked 2026-08-30

Selank compared with medazepam in 62 people

Peptide briefs that use this sourceSelank
Open source
167
Human clinical studyPubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2014Checked 2026-08-30

Selank compared with phenazepam in 60 people

Peptide briefs that use this sourceSelank
Open source
168
Randomized trialPubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2015Checked 2026-08-30

Phenazepam alone compared with phenazepam plus Selank in 70 people

Peptide briefs that use this sourceSelank
Open source
169
Human pharmacologyPubMed · Doklady Biological Sciences · 2020Checked 2026-08-30

Selank, Semax, and placebo brain-scan study in 52 healthy people

Peptide briefs that use this sourceSelank
Open source
170
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Drugs@FDA approved-drug search

Peptide briefs that use this sourceSelankP21 peptide
Open source
171
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA Global Substance Registration System record for emideltide (DSIP)

Peptide briefs that use this sourceDSIP
Open source
172
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA evaluation of emideltide (DSIP) and related bulk drug substances

Peptide briefs that use this sourceDSIP
Open source
173
ReferencePubMed · 1978Checked 2026-08-30

DSIP amino-acid sequence, synthesis, and activity

Peptide briefs that use this sourceDSIP
Open source
174
Randomized trialPubMed · 1981Checked 2026-08-30

Acute and delayed effects of DSIP on human sleep behavior

Peptide briefs that use this sourceDSIP
Open source
175
Human clinical studyPubMed · 1981Checked 2026-08-30

Synthetic DSIP and disturbed human sleep

Peptide briefs that use this sourceDSIP
Open source
176
Human clinical studyPubMed · 1981Checked 2026-08-30

Synthetic DSIP and sleep in people with insomnia

Peptide briefs that use this sourceDSIP
Open source
177
Human clinical studyPubMed · 1987Checked 2026-08-30

DSIP and 24-hour sleep-wake behavior in severe chronic insomnia

Peptide briefs that use this sourceDSIP
Open source
178
Randomized trialPubMed · 1987Checked 2026-08-30

DSIP efficacy study in chronic insomnia

Peptide briefs that use this sourceDSIP
Open source
179
Randomized trialPubMed · 1992Checked 2026-08-30

Double-blind DSIP study in chronic insomnia

Peptide briefs that use this sourceDSIP
Open source
180
Human pilotPubMed · 1984Checked 2026-08-30

DSIP and narcolepsy

Peptide briefs that use this sourceDSIP
Open source
181
Human clinical studyPubMed · 1984Checked 2026-08-30

DSIP in withdrawal syndromes from alcohol and opiates

Peptide briefs that use this sourceDSIP
Open source
182
Human pilotPubMed · 1998Checked 2026-08-30

Opioid detoxification with DSIP: open clinical trial

Peptide briefs that use this sourceDSIP
Open source
183
Human pharmacologyPubMed · 1989Checked 2026-08-30

Intravenous DSIP and a blood hormone change in people

Peptide briefs that use this sourceDSIP
Open source
184
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA Global Substance Registration System record for ropocamptide (LL-37)

Peptide briefs that use this sourceLL-37
Open source
185
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA Global Substance Registration System record for LL-37 amide

Peptide briefs that use this sourceLL-37
Open source
186
ReferencePubMed · 2001Checked 2026-08-30

Human cathelicidin precursor processing to LL-37

Peptide briefs that use this sourceLL-37
Open source
187
Randomized trialPubMed · 2014Checked 2026-08-30

Early randomized trial of topical LL-37 in venous leg ulcers

Peptide briefs that use this sourceLL-37
Open source
188
Randomized trialPubMed · 2021Checked 2026-08-30

Later randomized trial of LL-37 in venous leg ulcers

Peptide briefs that use this sourceLL-37
Open source
189
Randomized trialPubMed · 2023Checked 2026-08-30

Randomized study of topical LL-37 in diabetic foot ulcers

Peptide briefs that use this sourceLL-37
Open source
190
Trial registryClinicalTrials.gov · 2014Checked 2026-08-30

LL-37 melanoma study record (NCT02225366)

Peptide briefs that use this sourceLL-37
Open source
191
Randomized trialPubMed · 2023Checked 2026-08-30

Engineered Lactococcus lactis producing recombinant LL-37 in COVID-19

Peptide briefs that use this sourceLL-37
Open source
192
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Pharmacy Compounding Advisory Committee meeting planning

Peptide briefs that use this sourceLL-37
Open source
193
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA substance record for P-21, P021, and P21

Peptide briefs that use this sourceP21 peptide
Open source
194
PreclinicalPubMed · FEBS Letters · 2010Checked 2026-08-30

P21 learning, memory, and nerve-cell study in normal mice

Peptide briefs that use this sourceP21 peptide
Open source
195
PreclinicalPubMed · Neurobiology of Disease · 2014Checked 2026-08-30

Chronic P021 study in an Alzheimer-like mouse model

Peptide briefs that use this sourceP21 peptide
Open source
196
PreclinicalPubMed · Alzheimer’s Research & Therapy · 2017Checked 2026-08-30

Early P021 study in an Alzheimer-like mouse model

Peptide briefs that use this sourceP21 peptide
Open source
197
PreclinicalPubMed · Journal of Alzheimer’s Disease · 2015Checked 2026-08-30

P021 tau study in aged rats

Peptide briefs that use this sourceP21 peptide
Open source
198
PreclinicalPubMed · Journal of Neurodevelopmental Disorders · 2024Checked 2026-08-30

P021 study in lab-grown human nerve cells and a mouse model

Peptide briefs that use this sourceP21 peptide
Open source
199
Trial registryClinicalTrials.gov · 2026Checked 2026-08-30

ClinicalTrials.gov intervention search for P021

Peptide briefs that use this sourceP21 peptide
Open source
200
ReferenceNational Center for Biotechnology Information · 2026Checked 2026-08-30

NCBI Gene record for human CDKN1A, also called p21

Peptide briefs that use this sourceP21 peptide
Open source

Sources

How this source index works

This index covers sources from the peptide evidence briefs. Each source appears once, followed by the briefs that use it. Guide citations remain on their guide pages. Seeing a source here does not mean that it supports every claim about that peptide.